Abbott Laboratories Return on Investment 2012-2026 | ABT
Current and historical return on investment (ROI) values for Abbott Laboratories (ABT) over the last 10 years.
| Abbott Laboratories ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2026-06-30 | $7.35B | $72.31B | 10.16% |
| 2026-03-31 | $7.71B | $67.91B | 11.35% |
| 2025-12-31 | $8.05B | $62.77B | 12.83% |
| 2025-09-30 | $7.71B | $62.24B | 12.39% |
| 2025-06-30 | $7.52B | $59.74B | 12.58% |
| 2025-03-31 | $7.13B | $56.97B | 12.52% |
| 2024-12-31 | $6.83B | $54.42B | 12.54% |
| 2024-09-30 | $6.69B | $52.40B | 12.77% |
| 2024-06-30 | $6.48B | $52.23B | 12.41% |
| 2024-03-31 | $6.36B | $52.05B | 12.21% |
| 2023-12-31 | $6.48B | $52.10B | 12.43% |
| 2023-09-30 | $6.00B | $51.85B | 11.58% |
| 2023-06-30 | $6.13B | $51.61B | 11.87% |
| 2023-03-31 | $6.96B | $51.98B | 13.39% |
| 2022-12-31 | $8.36B | $52.20B | 16.02% |
| 2022-09-30 | $9.44B | $52.67B | 17.91% |
| 2022-06-30 | $10.21B | $52.90B | 19.31% |
| 2022-03-31 | $9.23B | $52.42B | 17.60% |
| 2021-12-31 | $8.43B | $52.06B | 16.18% |
| 2021-09-30 | $8.48B | $51.62B | 16.43% |
| 2021-06-30 | $7.43B | $51.08B | 14.54% |
| 2021-03-31 | $6.71B | $50.43B | 13.30% |
| 2020-12-31 | $5.36B | $49.42B | 10.84% |
| 2020-09-30 | $4.31B | $48.53B | 8.89% |
| 2020-06-30 | $4.02B | $48.46B | 8.29% |
| 2020-03-31 | $4.55B | $48.93B | 9.30% |
| 2019-12-31 | $4.53B | $49.62B | 9.13% |
| 2019-09-30 | $4.31B | $50.15B | 8.59% |
| 2019-06-30 | $4.11B | $50.28B | 8.16% |
| 2019-03-31 | $3.78B | $50.21B | 7.53% |
| 2018-12-31 | $3.65B | $50.90B | 7.17% |
| 2018-09-30 | $3.14B | $52.96B | 5.92% |
| 2018-06-30 | $2.91B | $54.30B | 5.36% |
| 2018-03-31 | $2.41B | $55.55B | 4.35% |
| 2017-12-31 | $1.56B | $56.19B | 2.78% |
| 2017-09-30 | $1.70B | $51.96B | 3.28% |
| 2017-06-30 | $1.83B | $44.80B | 4.09% |
| 2017-03-31 | $2.26B | $37.60B | 6.01% |
| 2016-12-31 | $3.03B | $30.48B | 9.93% |
| 2016-09-30 | $3.05B | $26.93B | 11.34% |
| 2016-06-30 | $2.87B | $27.00B | 10.62% |
| 2016-03-31 | $2.78B | $27.54B | 10.10% |
| 2015-12-31 | $2.87B | $27.82B | 10.31% |
| 2015-09-30 | $2.88B | $27.28B | 10.56% |
| 2015-06-30 | $2.90B | $27.16B | 10.66% |
| 2015-03-31 | $2.84B | $26.69B | 10.65% |
| 2014-12-31 | $2.60B | $26.43B | 9.83% |
| 2014-09-30 | $2.19B | $27.34B | 8.00% |
| 2014-06-30 | $1.93B | $27.46B | 7.04% |
| 2014-03-31 | $1.88B | $27.14B | 6.94% |
| 2013-12-31 | $2.13B | $26.96B | 7.91% |
| 2013-09-30 | $1.69B | $31.02B | 5.45% |
| 2013-06-30 | $1.53B | $34.01B | 4.50% |
| 2013-03-31 | $1.47B | $36.70B | 3.99% |
| 2012-12-31 | $1.36B | $39.51B | 3.44% |
| 2012-09-30 | $3.47B | $37.43B | 9.26% |
| 2012-06-30 | $3.75B | $37.08B | 10.11% |
| 2012-03-31 | $4.96B | $37.71B | 13.15% |
| 2011-12-31 | $5.75B | $37.68B | 15.26% |
| 2011-09-30 | $5.50B | $37.36B | 14.72% |
| 2011-06-30 | $6.09B | $36.51B | 16.67% |
| 2011-03-31 | $5.92B | $34.89B | 16.96% |
| 2010-12-31 | $6.09B | $33.55B | 18.15% |
| 2010-09-30 | $6.12B | $33.34B | 18.36% |
| 2010-06-30 | $6.58B | $32.98B | 19.95% |
| 2010-03-31 | $6.65B | $32.65B | 20.35% |
| 2009-12-31 | $6.24B | $32.09B | 19.43% |
| 2009-09-30 | $6.12B | $30.03B | 20.36% |
| 2009-06-30 | $5.87B | $28.95B | 20.28% |
| 2009-03-31 | $5.61B | $28.26B | 19.85% |
| 2008-12-31 | $5.70B | $27.60B | 20.63% |
| 2008-09-30 | $5.47B | $27.87B | 19.63% |
| 2008-06-30 | $5.00B | $26.24B | 19.06% |
| 2008-03-31 | $4.78B | $24.59B | 19.43% |
| 2007-12-31 | $4.58B | $23.05B | 19.87% |
| 2007-09-30 | $2.83B | $21.49B | 13.17% |
| 2007-06-30 | $2.59B | $21.75B | 11.91% |
| 2007-03-31 | $1.95B | $22.11B | 8.81% |
| 2006-12-31 | $2.04B | $21.54B | 9.48% |
| 2006-09-30 | $3.58B | $21.02B | 17.01% |
| 2006-06-30 | $3.72B | $19.56B | 19.01% |
| 2006-03-31 | $4.27B | $18.50B | 23.08% |
| 2005-12-31 | $4.36B | $18.57B | 23.50% |
| 2005-09-30 | $4.19B | $18.60B | 22.53% |
| 2005-06-30 | $4.38B | $18.69B | 23.45% |
| 2005-03-31 | $4.08B | $18.30B | 22.32% |
| 2004-12-31 | $3.90B | $18.20B | 21.42% |
| 2004-09-30 | $3.71B | $17.55B | 21.16% |
| 2004-06-30 | $3.51B | $17.07B | 20.57% |
| 2004-03-31 | $2.94B | $16.74B | 17.58% |
| 2003-12-31 | $2.97B | $16.04B | 18.54% |
| 2003-09-30 | $2.54B | $15.64B | 16.24% |
| 2003-06-30 | $2.63B | $15.45B | 17.04% |
| 2003-03-31 | $3.09B | $14.97B | 20.62% |
| 2002-12-31 | $3.15B | $14.50B | 21.74% |
| 2002-09-30 | $3.36B | $14.12B | 23.78% |
| 2002-06-30 | $3.19B | $13.62B | 23.42% |
| 2002-03-31 | $3.10B | $13.26B | 23.41% |
| 2001-12-31 | $1.90B | $12.11B | 15.65% |
| 2001-09-30 | $2.10B | $11.17B | 18.82% |
| 2001-06-30 | $2.14B | $10.27B | 20.87% |
| 2001-03-31 | $2.39B | $9.43B | 25.30% |
| 2000-12-31 | $3.40B | $9.44B | 36.04% |
| 2000-09-30 | $3.27B | $9.22B | 35.50% |
| 2000-06-30 | $3.06B | $8.87B | 34.53% |
| 2000-03-31 | $3.05B | $8.44B | 36.16% |
| 1999-12-31 | $3.12B | $7.99B | 39.02% |
| 1999-09-30 | $3.17B | $7.56B | 41.88% |
| 1999-06-30 | $3.29B | $7.24B | 45.52% |
| 1999-03-31 | $3.24B | $6.91B | 46.98% |
| 1998-12-31 | $3.13B | $6.63B | 47.25% |
| 1998-09-30 | $3.07B | $6.35B | 48.35% |
| 1998-06-30 | $2.99B | $6.11B | 48.83% |
| 1998-03-31 | $2.92B | $5.97B | 48.89% |
| 1997-12-31 | $2.85B | $5.84B | 48.77% |
| 1997-09-30 | $2.79B | $5.80B | 48.04% |
| 1997-06-30 | $2.74B | $5.70B | 48.04% |
| 1997-03-31 | $2.68B | $5.50B | 48.69% |
| 1996-12-31 | $2.62B | $5.31B | 49.35% |
| 1996-09-30 | $2.56B | $5.08B | 50.40% |
| 1996-06-30 | $2.53B | $4.90B | 51.51% |
| 1996-03-31 | $2.47B | $4.81B | 51.38% |
| 1995-12-31 | $2.38B | $4.66B | 51.14% |
| 1995-09-30 | $2.32B | $4.54B | 51.09% |
| 1995-06-30 | $2.26B | $4.42B | 51.04% |
| 1995-03-31 | $2.21B | $4.30B | 51.36% |
| 1994-12-31 | $2.14B | $4.21B | 50.97% |
| 1994-09-30 | $2.10B | $4.12B | 50.95% |
| 1994-06-30 | $2.06B | $3.98B | 51.80% |
| 1994-03-31 | $1.94B | $3.85B | 50.30% |
| 1993-12-31 | $1.85B | $3.72B | 49.85% |
| 1993-09-30 | $1.78B | $3.59B | 49.58% |
| 1993-06-30 | $1.78B | $3.52B | 50.43% |
| 1993-03-31 | $1.77B | $3.48B | 51.04% |
| 1992-12-31 | $1.74B | $3.44B | 50.63% |
| 1992-09-30 | $1.73B | $3.41B | 50.87% |
| 1992-06-30 | $1.64B | $3.33B | 49.30% |
| 1992-03-31 | $1.60B | $3.24B | 49.35% |
| 1991-12-31 | $1.56B | $3.16B | 49.33% |
| 1991-09-30 | $1.50B | $3.07B | 48.88% |
| 1991-06-30 | $1.47B | $2.99B | 49.12% |
| 1991-03-31 | $1.45B | $2.94B | 49.35% |
| 1990-12-31 | $1.41B | $2.90B | 48.59% |
| 1990-09-30 | $1.37B | $2.87B | 47.60% |
| 1990-06-30 | $1.32B | $2.88B | 45.90% |
| 1990-03-31 | $1.27B | $2.87B | 44.20% |
| 1989-12-31 | $1.22B | $2.86B | 42.74% |
| 1989-09-30 | $1.17B | $2.85B | 41.20% |
| 1989-06-30 | $1.14B | $2.78B | 41.10% |
| 1989-03-31 | $1.12B | $2.72B | 41.14% |
| 1988-12-31 | $1.10B | $2.61B | 42.30% |
| 1988-09-30 | $1.09B | $2.49B | 43.57% |
| 1988-06-30 | $1.07B | $2.40B | 44.68% |
| 1988-03-31 | $1.04B | $2.30B | 45.14% |
| 1987-12-31 | $1.01B | $2.23B | 45.06% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $177.555B | $44.328B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $117.847B | 16.11 |
| Stryker (SYK) | United States | $105.529B | 19.72 |
| EssilorLuxottica (ESLOY) | France | $73.880B | 0.00 |
| Boston Scientific (BSX) | United States | $62.810B | 13.50 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.597B | 0.00 |
| Agilent Technologies (A) | United States | $44.113B | 25.82 |
| Medline (MDLN) | United States | $41.597B | 0.00 |
| ResMed (RMD) | United States | $32.455B | 20.14 |
| GE HealthCare Technologies (GEHC) | United States | $28.967B | 13.85 |
| Koninklijke Philips (PHG) | Netherlands | $24.258B | 12.92 |
| Terumo (TRUMY) | Japan | $20.887B | 19.94 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.189B | 11.25 |
| Baxter (BAX) | United States | $11.788B | 11.12 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.573B | 0.00 |
| Demant (WILYY) | Denmark | $10.101B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.064B | 40.56 |
| Insulet (PODD) | United States | $9.751B | 23.95 |
| Sunny Optical Technology (SNPTF) | China | $9.508B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.563B | 20.19 |
| Raia Drogasil SA - (RADLY) | Brazil | $5.024B | 0.00 |
| BillionToOne (BLLN) | United States | $4.998B | 151.31 |
| Haemonetics (HAE) | United States | $4.932B | 21.64 |
| DiaSorin S.p.A (DSRLF) | Italy | $4.705B | 0.00 |
| ICU Medical (ICUI) | United States | $3.815B | 22.78 |
| Envista Holdings (NVST) | United States | $3.750B | 15.88 |
| AtriCure (ATRC) | United States | $2.955B | 252.61 |
| Neogen (NEOG) | United States | $2.835B | 50.00 |
| Curaleaf Holdings (CURLF) | United States | $2.445B | 0.00 |
| Curaleaf Holdings (CURLD) | Canada | $2.388B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.265B | 0.00 |
| Trulieve Cannabis (TRLV) | United States | $2.132B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.130B | 10.17 |
| Perrigo (PRGO) | Ireland | $1.882B | 5.42 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.810B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.804B | 29.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $1.798B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.795B | 229.31 |
| Kestra Medical Technologies (KMTS) | United States | $1.455B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.426B | 15.21 |
| Phibro Animal Health (PAHC) | United States | $1.403B | 10.77 |
| Omeros (OMER) | United States | $1.294B | 6.55 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.065B | 0.00 |
| CeriBell (CBLL) | United States | $0.935B | 0.00 |
| InMode (INMD) | Israel | $0.825B | 11.48 |
| AdaptHealth (AHCO) | United States | $0.779B | 16.31 |
| VAREX IMAGING (VREX) | United States | $0.778B | 17.12 |
| Glass House Brands (GLAS) | United States | $0.748B | 0.00 |
| QuidelOrtho (QDEL) | United States | $0.728B | 7.87 |
| Valneva SE (VALN) | France | $0.622B | 0.00 |
| Brainsway (BWAY) | Israel | $0.547B | 30.93 |
| Tilray Brands (TLRY) | Canada | $0.543B | 0.00 |
| Cerus (CERS) | United States | $0.534B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.527B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.521B | 0.00 |
| Evolus (EOLS) | United States | $0.519B | 0.00 |
| Vireo Growth (VREOD) | United States | $0.451B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.443B | 0.00 |
| Verano Holdings (VRNOD) | United States | $0.425B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.420B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.395B | 8.28 |
| Cresco Labs (CRLBF) | United States | $0.377B | 0.00 |
| SNDL (SNDL) | Canada | $0.353B | 0.00 |
| Village Farms (VFF) | Canada | $0.347B | 15.78 |
| Viemed Healthcare (VMD) | United States | $0.339B | 24.75 |
| Sanara MedTech (SMTI) | United States | $0.322B | 159.41 |
| TriSalus Life Sciences (TLSI) | United States | $0.314B | 0.00 |
| MacroGenics (MGNX) | United States | $0.264B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.251B | 13.34 |
| OraSure Technologies (OSUR) | United States | $0.246B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.235B | 22.55 |
| High Tide (HITI) | Canada | $0.230B | 51.60 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Exagen (XGN) | United States | $0.204B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.202B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.197B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Jin Medical (ZJYL) | China | $0.156B | 0.00 |
| Organigram Global (OGI) | Canada | $0.148B | 0.00 |
| Quanterix (QTRX) | United States | $0.145B | 0.00 |
| Apyx Medical (APYX) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| ImmuCell (ICCC) | United States | $0.090B | 124.38 |
| FitLife Brands (FTLF) | United States | $0.088B | 11.51 |
| Jushi Holdings (JUSHF) | United States | $0.083B | 0.00 |
| Accendra Health (ACH) | United States | $0.068B | 3.87 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| InterCure (INCR) | Israel | $0.058B | 0.00 |
| Hongchang (HCIL) | China | $0.055B | 0.00 |
| Biote (BTMD) | United States | $0.049B | 4.00 |
| Nephros (NEPH) | United States | $0.047B | 39.18 |
| Veru (VERU) | United States | $0.041B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.039B | 18.96 |
| United-Guardian (UG) | United States | $0.033B | 13.35 |
| Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.023B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.018B | 0.00 |
| Bonk (BNKK) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.001B | 0.00 |
| INLIF (INLF) | China | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |